Better analysis for better decisions: Facing up to the challenges

PharmacoEconomics

Volumn 24, Issue 11, 2006, Pages 1039-1042

  Drummond, Michael F ^a   Sculpher, Mark J ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALGORITHM; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; MEDICAL DECISION MAKING; MEDICAL RESEARCH; METHODOLOGY; PRIORITY JOURNAL;

EID: 33750600963     PISSN: 11707690     EISSN: 11707690     Source Type: Journal    
DOI: 10.2165/00019053-200624110-00001     Document Type: Conference Paper

References (14)

1. Weinstein MC. Recent developments in decision-analytic modelling for economic evaluation. Pharmacoeconomics 2006; 24 (11): 1043-53
2. Claxton KP, Sculpher MJ. Using value of information analysis to prioritise health research: some lessons from recent UK experience. Pharmacoeconomics 2006; 24 (11): 1055-68
3. Torrance GW. Utility measurement in healthcare: the things I never got to. Pharmacoeconomics 2006; 24 (11): 1069-78
4. Briggs AH, Levy AR. Pharmacoeconomics and pharmacoepidemiology: curious bedfellows or a match made in heaven? Pharmacoeconomics 2006; 24 (11): 1079-86
5. Sculpher MJ, Drummond MF. Analysis sans frontières: can we ever make economic evaluations generalisable across jurisdictions? Pharmacoeconomics 2006; 24 (11): 1087-99
6. Manca A, Willan AR. 'Lost in translation': accounting for between-country differences in the analysis of multinational cost-effectiveness data. Pharmacoeconomics 2006; 24 (11): 1101-19
7. Birch S, Gafni A. Information created to evade reality (ICER): things we should not look to for answers. Pharmacoeconomics 2006; 24 (11): 1121-31
8. Buxton MJ. Economic evaluation and decision making in the UK. Pharmacoeconomics 2006; 24 (11): 1133-43
9. Goeree R, Levin L. Building bridges between academic research and policy formulation: the PRUFE framework - an integral part of Ontario's evidence-based HTPA process. Pharmacoeconomics 2006; 24 (11): 1145-58
10. Laupacis A. Economic evaluations in the Canadian common drug review. Pharmacoeconomics 2006; 24 (11): 1159-64
11. Neumann PJ, Sullivan SD. Economic evaluation in the US: what is the missing link? Pharmacoeconomics 2006; 24 (11): 1165-70
12. Briggs A, Buxton M, Drummond MF, et al. Unfinished sympathy: a tribute to the life and career of Bernie O'Brien (1959-2004). Med Decis Making 2004; 24 (5): 538-44
13. Gold M, Seigel J, Russell L, et al. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996
14. National Institute for Health and Clinical Excellence (NICE). Guide to the methods of technology appraisal. London: NICE, 2004